Market Summary
USD40.68-0.38
Market Closed-0.93%
SUPN Alerts
SUPN Stock Price
SUPN RSI Chart
SUPN Valuation
SUPN Price/Sales (Trailing)
SUPN Profitability
SUPN Fundamentals
SUPN Revenue
SUPN Earnings
Price Action
52 Week Range
24.9541.70
(Low)(High)
Last 7 days
0.9%
Last 30 days
13.8%
Last 90 days
17%
Trailing 12 Months
40.2%
SUPN Financial Health
SUPN Investor Care
Peers (Alternatives to Supernus Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
JNJ | 442.1B | 96.0B | -4.77% | 1.21% | 23.08 | 4.6 | 5.02% | 7.14% |
LLY | 308.1B | 29.2B | -6.33% | 46.49% | 51.07 | 10.54 | 5.34% | 1.02% |
MRK | 267.0B | 59.0B | -5.13% | 34.98% | 17.49 | 4.53 | 27.84% | 112.03% |
PFE | 245.5B | 99.9B | -13.80% | -15.92% | 8.25 | 2.46 | 45.01% | 53.21% |
BMY | 154.0B | 46.7B | 0.64% | 15.96% | 23.07 | 3.3 | 2.79% | 223.53% |
| MID-CAP | ||||||||
PRGO | 5.0B | 4.4B | 10.03% | -0.57% | -46.66 | 1.14 | 1.80% | 57.67% |
SUPN | 2.2B | 659.0M | 13.79% | 40.18% | 57.51 | 3.29 | 16.78% | -53.92% |
| SMALL-CAP | ||||||||
TLRY | 1.9B | 613.6M | 24.42% | -38.51% | -3.79 | 3.14 | 37.73% | -7.19% |
RETA | 1.6B | 3.1M | 23.90% | 79.89% | -5.08 | 503.44 | -77.09% | -12.24% |
CGC | 1.4B | - | 33.79% | -57.23% | -0.46 | 1.95 | -4.11% | -144.36% |
ACRS | 1.2B | 23.5M | 12.85% | 73.07% | -14.2 | 49.6 | 243.57% | -1.04% |
CRON | 942.1M | 112.7M | - | -24.55% | -4.21 | 8.36 | 45.53% | 40.26% |
INVA | 885.5M | - | -2.61% | -19.99% | 2.65 | 2.34 | 10.49% | -16.07% |
OCUL | 298.8M | 49.7M | 46.97% | -25.95% | -5.03 | 6.01 | 28.95% | 32.80% |
ENDP | 94.1M | 2.6B | -43.99% | -88.43% | -0.03 | 0.04 | -13.88% | -4855.92% |
Financials for Supernus Pharmaceuticals
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
| Revenue | 4.6% | 659 | 630 | 601 | 580 | 564 |
| S&GA Expenses | 11.0% | 405 | 365 | 334 | 305 | 260 |
| R&D Expenses | -0.1% | 78 | 78 | 77 | 90 | 87 |
| Costs and Expenses | 10.9% | 641 | 578 | 527 | 494 | 441 |
| EBITDA | -16.2% | 96 | 114 | 108 | 108 | - |
| EBITDA Margin | -19.9% | 0.15* | 0.18* | 0.18* | 0.19* | - |
| Earnings Before Taxes | -51.5% | 28 | 57 | 77 | 73 | 111 |
| EBT Margin | -53.7% | 0.04* | 0.09* | 0.13* | 0.13* | - |
| Interest Expenses | -79.3% | -9.50 | -5.30 | -1.64 | 3 | 2 |
| Net Income | -34.5% | 38 | 57 | 73 | 53 | 82 |
| Net Income Margin | -37.3% | 0.06* | 0.09* | 0.12* | 0.09* | - |
| Free Cahsflow | 14.9% | 138 | 120 | 93 | 125 | - |
* denotes actual numbers (not divided by Millions)
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
| Assets | -0.1% | 1,693 | 1,695 | 1,640 | 1,689 | 1,555 |
| Current Assets | 6.2% | 664 | 625 | 569 | 602 | 668 |
| Cash Equivalents | -35.7% | 111 | 173 | 116 | 203 | 215 |
| Inventory | -2.0% | 83 | 85 | 89 | 86 | 60 |
| Net PPE | 1.5% | 17 | 17 | - | - | - |
| Goodwill | 1.7% | 117 | 115 | 115 | 118 | 40 |
| Liabilities | -1.5% | 840 | 854 | 811 | 873 | 745 |
| Current Liabilities | -1.3% | 726 | 736 | 285 | 315 | 235 |
| LT Debt, Current | 0.1% | 401 | 401 | - | - | - |
| LT Debt, Non Current | NaN% | - | - | 379 | - | - |
| Shareholder's Equity | 1.4% | 853 | 841 | 828 | 816 | 810 |
| Retained Earnings | 0.4% | 456 | 454 | 446 | 380 | 377 |
| Additional Paid-In Capital | 2.9% | 401 | 390 | 383 | 434 | 429 |
| Accumulated Depreciation | 6.0% | 13 | 12 | 12 | 16 | - |
| Shares Outstanding | 0% | 53 | 53 | 53 | 53 | 53 |
* denotes actual numbers (not divided by Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
| Cashflow From Operations | 14.9% | 138 | 120 | 95 | 127 | 110 |
| Share Based Compensation | 5.8% | 17 | 16 | 18 | 18 | 17 |
| Cashflow From Investing | -502.2% | -91.77 | -15.24 | -80.45 | -81.91 | -108.70 |
| Cashflow From Financing | 3.3% | -150.05 | -155.18 | -154.70 | -130.42 | 9 |
Risks for SUPN
What is the probability of a big loss on SUPN?
100%
Probability that Supernus Pharmaceuticals stock will be more than 20% underwater in next one year
45%
Probability that Supernus Pharmaceuticals stock will be more than 30% underwater in next one year.
38.1%
Probability that Supernus Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SUPN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Supernus Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Returns for SUPN
Cumulative Returns on SUPN
18.4%
10-Year Cumulative Returns
20.0%
7-Year Cumulative Returns
-0.4%
5-Year Cumulative Returns
19.6%
3-Year Cumulative Returns
What are the long-term rolling returns for SUPN?
FIve years rolling returns for Supernus Pharmaceuticals.
Annualized Returns
Which funds bought or sold SUPN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-01-26 | Empowered Funds, LLC | new | - | 1,680,000 | 1,680,000 | 0.11% |
2023-01-26 | State of Tennessee, Treasury Department | added | 12.01 | 252,000 | 1,064,000 | -% |
2023-01-26 | Stephens Investment Management Group LLC | reduced | -0.06 | 3,222,000 | 57,579,000 | 1.04% |
2023-01-26 | OREGON PUBLIC EMPLOYEES RETIREMENT FUND | reduced | -0.17 | 30,899 | 627,899 | 0.01% |
2023-01-26 | STRS OHIO | unchanged | - | 1,000 | 28,000 | -% |
2023-01-26 | Eagle Bay Advisors LLC | added | 19.28 | 22,645 | 113,645 | 0.06% |
2023-01-26 | COMERICA BANK | reduced | -21.53 | -102,000 | 1,303,000 | 0.01% |
2023-01-26 | CAMPBELL NEWMAN ASSET MANAGEMENT INC | added | 3.26 | 72,925 | 894,925 | 0.09% |
2023-01-25 | Bridge City Capital, LLC | reduced | -0.71 | 100,000 | 2,248,000 | 1.15% |
2023-01-25 | Mayflower Financial Advisors, LLC | unchanged | - | 563 | 24,563 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
SUPN Alerts
Supernus Pharmaceuticals News
Schedule 13G FIlings of Supernus Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jan 23, 2023 | blackrock inc. | 17.8% | 9,604,073 | SC 13G/A | |
| Feb 15, 2022 | armistice capital, llc | 7.8% | 4,136,000 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 15.9% | 8,451,022 | SC 13G/A | |
| Jan 26, 2022 | blackrock inc. | 15.9% | 8,451,022 | SC 13G/A | |
| Feb 16, 2021 | armistice capital, llc | 5.9% | 3,120,000 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.06% | 5,298,078 | SC 13G/A | |
| Jan 25, 2021 | blackrock inc. | 16.9% | 8,912,801 | SC 13G | |
| Mar 12, 2020 | armistice capital, llc | 5.5% | 2,888,000 | SC 13G | |
| Feb 12, 2020 | vanguard group inc | 10.11% | 5,305,889 | SC 13G/A | |
| Feb 10, 2020 | blackrock inc. | 16.6% | 8,734,832 | SC 13G/A |
SUPN Fair Value
Recent SEC filings of Supernus Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Jan 23, 2023 | SC 13G/A | Major Ownership Report | |
| Jan 20, 2023 | 4 | Insider Trading | |
| Jan 19, 2023 | 4 | Insider Trading | |
| Jan 19, 2023 | 4 | Insider Trading | |
| Jan 17, 2023 | 4 | Insider Trading | |
| Jan 17, 2023 | 4 | Insider Trading | |
| Jan 17, 2023 | 4 | Insider Trading | |
| Jan 13, 2023 | 4/A | Insider Trading | |
| Jan 13, 2023 | 4/A | Insider Trading | |
| Jan 12, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for SUPN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-01-18 | Khattar Jack A. | acquired | 77,244.8 | 9.56 | 8,080 | president, ceo |
2023-01-18 | Khattar Jack A. | sold | -199,394 | 40.3959 | -4,936 | president, ceo |
2023-01-17 | Bhatt Padmanabh P. | acquired | 44,061.4 | 9.13 | 4,826 | sr. vp of ip, cso |
2023-01-17 | Khattar Jack A. | acquired | 400,755 | 9.56 | 41,920 | president, ceo |
2023-01-17 | Bhatt Padmanabh P. | sold | -192,638 | 39.9167 | -4,826 | sr. vp of ip, cso |
2023-01-17 | Khattar Jack A. | sold | -1,018,730 | 40.0349 | -25,446 | president, ceo |
2023-01-10 | Hudson Frederick M. | acquired | 68,903.8 | 7.9 | 8,722 | - |
2023-01-06 | Bhatt Padmanabh P. | acquired | 1,588.62 | 9.13 | 174 | sr. vp of ip, cso |
2023-01-06 | Bhatt Padmanabh P. | sold | -6,942.6 | 39.9 | -174 | sr. vp of ip, cso |
2022-12-28 | NEWHALL CHARLES W III | acquired | 206,711 | 7.9 | 26,166 | - |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
SUPN Income Statement
2022-09-30Condensed Consolidated Statements of Earnings - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |||
| Revenues | ||||||
| Total revenues | $ 177,353 | $ 148,464 | $ 499,910 | $ 420,725 | ||
| Costs and expenses | ||||||
| Cost of goods sold | [1] | 25,878 | 18,085 | 64,267 | 58,067 | |
| Research and development | 19,554 | 19,654 | 56,778 | 69,389 | ||
| Selling, general and administrative | 112,314 | 72,032 | 303,249 | 203,024 | ||
| Amortization of intangible assets | 20,644 | 6,009 | 61,932 | 17,964 | ||
| Contingent consideration expense (gain) | 486 | 80 | 1,894 | (7,650) | ||
| Total costs and expenses | 178,876 | 115,860 | 488,120 | 340,794 | ||
| Operating earnings (loss) | (1,523) | 32,604 | 11,790 | 79,931 | ||
| Other income (expense) | ||||||
| Interest expense | (1,724) | (5,925) | (5,476) | (17,489) | ||
| Interest and other income, net | 2,803 | 2,281 | 19,289 | 8,682 | ||
| Total other income (expense) | 1,079 | (3,644) | 13,813 | (8,807) | ||
| Earnings (Loss) before income taxes | (444) | 28,960 | 25,603 | 71,124 | ||
| Income tax (benefit) expense | (2,193) | 7,398 | (9,627) | 20,142 | ||
| Net earnings | $ 1,749 | $ 21,562 | $ 35,230 | $ 50,982 | ||
| Earnings per share | ||||||
| Basic (in dollars per share) | $ 0.03 | $ 0.41 | $ 0.66 | $ 0.96 | ||
| Diluted (in dollars per share) | $ 0.03 | $ 0.40 | $ 0.62 | $ 0.94 | ||
| Weighted average shares outstanding | ||||||
| Basic (in shares) | 53,789,674 | 53,187,764 | 53,517,838 | 53,053,441 | ||
| Diluted (in shares) | 55,034,838 | 54,334,794 | 61,543,121 | 54,301,461 | ||
| Net product sales | ||||||
| Revenues | ||||||
| Total revenues | $ 172,724 | $ 145,532 | $ 485,647 | $ 412,541 | ||
| Royalty revenues | ||||||
| Revenues | ||||||
| Total revenues | $ 4,629 | $ 2,932 | $ 14,263 | $ 8,184 | ||
| ||||||
SUPN Balance Sheet
2022-09-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 111,492 | $ 203,434 |
| Marketable securities | 280,297 | 136,246 |
| Accounts receivable, net | 164,086 | 148,932 |
| Inventories, net | 83,165 | 85,959 |
| Prepaid expenses and other current assets | 24,846 | 27,019 |
| Total current assets | 663,886 | 601,590 |
| Long-term marketable securities | 131,937 | 119,166 |
| Property and equipment, net | 15,872 | 16,955 |
| Intangible assets, net | 722,761 | 784,693 |
| Goodwill | 117,383 | 117,516 |
| Other assets | 41,290 | 49,232 |
| Total assets | 1,693,129 | 1,689,152 |
| Current liabilities | ||
| Accounts payable and accrued liabilities | 110,302 | 117,683 |
| Accrued product returns and rebates | 158,470 | 132,724 |
| Contingent consideration, current portion | 47,590 | 44,840 |
| Convertible notes, net | 401,438 | 0 |
| Other current liabilities | 8,187 | 20,132 |
| Total current liabilities | 725,987 | 315,379 |
| Convertible notes, net | 0 | 379,252 |
| Contingent consideration, long-term | 9,781 | 35,637 |
| Operating lease liabilities, long-term | 36,028 | 41,298 |
| Deferred income tax liabilities | 58,164 | 85,355 |
| Other liabilities | 10,371 | 16,380 |
| Total liabilities | 840,331 | 873,301 |
| Stockholders’ equity | ||
| Common Stock, Value, Issued | 54 | 53 |
| Additional paid-in capital | 401,026 | 434,337 |
| Accumulated other comprehensive earnings (loss), net of tax | (4,046) | 1,539 |
| Retained earnings | 455,764 | 379,922 |
| Total stockholders’ equity | 852,798 | 815,851 |
| Total liabilities and stockholders’ equity | $ 1,693,129 | $ 1,689,152 |